Axsome Therapeutics, Inc. (AXSM) Earnings History
Net Loss13 years of earnings data (2013–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Axsome Therapeutics, Inc. (AXSM) Earnings Overview
As of June 23, 2026, Axsome Therapeutics, Inc. (AXSM) reported trailing twelve-month net income of -$188M, reflecting +38.6% year-over-year growth. The company earned $-3.68 per diluted share over the past four quarters, with a net profit margin of -28.7%.
Looking at the long-term picture, AXSM's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2013.
Axsome Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including INVA ($504M net income, 63.8% margin), SUPN (-$29M net income, -5.4% margin), ACAD ($376M net income, 36.5% margin), AXSM has room to improve margins relative to the peer group. Compare AXSM vs INVA →
AXSM Earnings vs Peers
Earnings metrics vs comparable public companies
AXSM Historical Earnings Data (2013–2025)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$183M | +36.2% | -$169M | $-3.68 | -28.7% | -26.5% |
| 2024 | -$287M | -20.1% | -$281M | $-5.99 | -74.5% | -72.7% |
| 2023 | -$239M | -27.8% | -$232M | $-5.27 | -88.4% | -85.7% |
| 2022 | -$187M | -43.5% | -$180M | $-4.60 | -374.0% | -359.3% |
| 2021 | -$130M | -26.7% | -$125M | $-3.47 | - | - |
| 2020 | -$103M | -50.6% | -$99M | $-2.83 | - | - |
| 2019 | -$68M | -120.7% | -$67M | $-2.05 | - | - |
| 2018 | -$31M | -7.0% | -$33M | $-1.15 | - | - |
| 2017 | -$29M | -6.4% | -$27M | $-1.27 | - | - |
| 2016 | -$27M | -122.8% | -$28M | $-1.42 | - | - |
| 2015 | -$12M | -103.5% | -$9M | $-0.88 | - | - |
| 2014 | -$6M | -177.0% | -$6M | $-0.47 | - | - |
| 2013 | -$2M | - | -$2M | $-0.28 | - | - |
Download Data
Export AXSM earnings history in CSV or JSON format
Free sign-in required to download data
Full Stock Analysis
Deep dive into AXSM consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AXSM — Frequently Asked Questions
Quick answers to the most common questions about buying AXSM stock.
What is AXSM earnings per share (EPS)?
AXSM trailing twelve-month (TTM) diluted EPS is $-3.68, reflecting +38.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2013 to 2025 is available in the table on this page.
What is Axsome Therapeutics, Inc.'s net income?
Axsome Therapeutics, Inc. (AXSM) trailing twelve-month net income is $-188M as of 2025. Earnings grew +38.6% year-over-year.
Is AXSM profitable?
AXSM is not currently profitable on a TTM basis, reporting a net loss of $-188M. Net margin is -28.7%. Investors should monitor for a return to profitability.
What is AXSM's earnings growth rate?
AXSM compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2013 to 2025.
What are AXSM's profit margins?
Axsome Therapeutics, Inc. net profit margin is -28.7%, operating margin is -26.5%, and gross margin is +92.6%. Below-average margins reflect competitive or cost pressures. Return on Equity is -252.1%.
Is AXSM growing earnings?
Yes, AXSM earnings are accelerating — EPS growth of +38.6% exceeds the 5-year CAGR of N/A. TTM net income reached $-188M. Earnings momentum is strengthening.
What was AXSM's best earnings year?
Axsome Therapeutics, Inc.'s highest annual net income on record is $-2M, achieved in fiscal year 2013. Earnings history on this page spans 2013 to 2025 and includes all annual and quarterly figures.
What were AXSM's earnings last quarter?
AXSM's most recent reported quarter was Q1 2026. Net income was $-65M with diluted EPS of $-1.26. For a full breakdown of all quarters, see the quarterly earnings table on this page.